Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

Figures

• 

  Figure 1. The trajectories of adjusted mean changes in body weight during the study in empagliflozin and placebo arms.

• 

  Figure 2. The trajectories of adjusted mean changes in body weight per mean daily dose of loop diuretics during the study in empagliflozin and placebo arms.

• 

  Figure 3. The trajectories of adjusted mean changes in haematocrit during the study in empagliflozin and placebo arms.

• 

  Figure 4. The win ratios for primary efficacy outcome* at Day 90 by median weight change at Days 15 and 30 in (A) the entire population (stratified by treatment group), (B) the placebo arm only (unstratified), and (C) the empagliflozin arm only (unstratified). *Hierarchical composite of death, number of heart failure events, time to first heart failure event and change from baseline in KCCQ-TSS after 90 days of treatment. The win ratio was calculated using a non-parametric generalized pairwise comparison procedure; data are presented as the point estimate and 95% CI with a two-sided P-value.

• 

  Figure 5. The win ratios for primary efficacy outcome* at Day 90 by median haematocrit change at Days 15 and 30 in (A) the entire population (stratified by treatment group), (B) the placebo arm only (unstratified), and (C) the empagliflozin arm only (unstratified). *Hierarchical composite of death, number of heart failure events, time to first heart failure event and change from baseline in KCCQ-TSS after 90 days of treatment. The win ratio was calculated using a non-parametric generalized pairwise comparison procedure; data are presented as the point estimate and 95% CI with a two-sided P-value.